乳腺癌随访和药物副作用管理策略的研究进展

乳腺癌是全球女性发病率最高的恶性肿瘤,随着诊断技术及治疗手段的不断提高,乳腺癌患者接受系统治疗后生存期明显延长。乳腺癌患者需要长时间的随访以便及早监测到局部复发和远处转移。此外,激素敏感性乳腺癌患者还需要给予5~10年的内分泌治疗,针对其副作用的全程管理也需要随访,进而提高患者的生活质量,减轻患者疾病负担。本文就近年来乳腺癌随访相关方面进行简要综述。     

风险管理在儿科急诊护理工作中的应用研究

目的研究风险管理在儿科急诊护理工作中的应用。方法选取2021年10月至12月间来我科室就诊的100例患儿作为研究对象,将其分为研究组、对照组两组,每组各50例患儿。运用常规护理模式护理对照组患儿,运用风险管理模式,为研究组患儿给予护理干预,分析二组发生不良护理事故的情况并统计护理满意度。结果研究期间,研究组不良护理事件发生率为2.0%,对照组不良护理事件发生率为12.0%；研究组对护理工作的满意度为98.0%,对照组对护理工作的满意度为84.0%,P<0.05,组间差异具统计学意义。结论将风险管理应用于儿科急诊护理工作,可降低不良事件发生几率,保障患儿安全,具有推广应用价值。     

A Pre-Protocol/Post-Protocol Quality Improvement Initiative Specific to One Hospital for Security of Pathologic Specimen

ObjectiveThe objective of this study was to reduce errors in a pathologic specimen with the help of a protocol systematizing the pathology specimen management process in the operating room.Materials and methodThis quasi-experimental study was carried out in the operating room unit of a research and training hospital. A protocol systematizing the process of specimen management in secure surgical pathology and prepared in light of the current literature was used as an intervention, and the effectiveness of the protocol was tested.ResultsIt was determined that the rate of adverse events decreased from .3226% (68 of 21,078) to .032% (6 of 18,706) after the protocol systematizing the surgical pathology specimen management process prepared by the researchers, and the protocol was found to be effective by 90% (P = .03).ConclusionBased on the data obtained in this study, we recommend the use of a pathologic specimen management protocol in the operating room.     

Fine particulate matter and incidence of metabolic syndrome in non-CVD patients: A nationwide population-based cohort study

Background

It has been reported that particulate matter (PM) is associated with cardiovascular diseases (CVD) while metabolic syndrome is also an important risk factor for CVD. However, few studies have investigated the epidemiological association between PM and metabolic syndrome.

Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry

Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC.